Searchable abstracts of presentations at key conferences in endocrinology

ea0073ap1.1 | The Geoffrey Harris Prize Lecture | ECE2021

Complex problems often have simple solution - let’s move on from Hippocrates!

Wass John

The philosophy of my research over the years has been to ask clinically relevant questions which will enhance the practice of decision making in endocrinology, based on scientific assessment of reasonable cohorts. In hitherto unpublished data, we have done work on the assessment of somatostatin responsive headaches in acromegaly and show that they persist over many years, may respond to radiotherapy and may also remain problematic even if acromegaly is cured. We have also look...

ea0094ens7.4 | Neuroendocrinology | SFEBES2023

The Pituitary Society International Consensus on the Treatment of Prolactinoma

Wass John

This review was published in Nature Reviews Endocrinology. It covers recent advances in treatment of pituitary tumours secreting prolactin including long-term adverse effects of dopamine agonist therapy, outcomes following dopamine agonists withdrawal, advances in surgical tumour resection. In addition, there are sections on management during pregnancy, effects of hyperprolactinemia on bone and fracture risk, the management of cystic and aggressive prolactinomas. Prolactinomas...

ea0005p105 | Diabetes, Metabolism and Cardiovascular | BES2003

Polycystic ovary syndrome (PCOS) in Sri Lankans

Wijeyaratne C , Balen A , Barth J , Belchetz P

PCOS has major long-term health implications that are closely linked to the Metabolic Syndrome. The prevalence of the Metabolic Syndrome is high among migrant and indigenous South Asian populations. We have previously demonstrated that migrant South Asians with PCOS have a greater degree of insulin resistance than white Europeans with PCOS. As there is a paucity of data on PCOS among indigenous South Asian populations, consecutive consenting anovular PCOS subjects (80) and age...

ea0081p427 | Pituitary and Neuroendocrinology | ECE2022

Long-term Tolvaptan therapy in the treatment of SIAD in Elderly- A case report with challenging cytochrome P 450 drug interactions

Madhurya Kethireddi Keerthi , Babu Parthasarathy Sathish

Background: Chronic SIAD with its disabling impact is challenging to manage in elderly patients as fluid restriction or demeclocycline often has a limited success. Tolvaptan is a novel selective antagonist of vasopressin receptor (V2R) which is safely used in patients with SIAD and other conditions with hypervolemia. We report a case of longest Tolvaptan use with significant challenges amongst our case series which we had previously publishedMethod: A Ca...

ea0030p1 | (1) | BSPED2012

A homozygous glutathione peroxidase 1 mutation, p. Arg130-Leu133del, in a patient with familial glucocorticoid deficiency

Kowalczyk Julia , Meimaridou Eirini , Guasti Leo , Clark Adrian J L , Metherell Lou A

Familial glucocorticoid deficiency is an autosomal recessive disorder characterised by resistance to ACTH of the adrenal cortex, leading to isolated glucocorticoid deficiency and life-threatening hypoglycaemia. Half of all cases are caused by mutations in MC2R, MRAP, MCM4 or STAR. Recent work in our group has identified defects in nicotinamide nucleotide transhydrogenase (NNT) to be causal in a further 10% of cases. NNT generates the high con...

ea0028oc1.6 | Young Endocrinologists prize session | SFEBES2012

A homozygous glutathione peroxidase 1 mutation, p. Arg130-Leu133del, in a patient with Familial Glucocorticoid Deficiency

Kowalczyk Julia , Meimaridou Eirini , Guasti Leonardo , Nurnberg Peter , Touraine Philippe , King Peter , Metherell Lou

Background: Familial Glucocorticoid Deficiency is an autosomal recessive disorder characterised by ACTH resistance of the adrenal cortex, leading to isolated glucocorticoid deficiency. Causative genes include MC2R, its accessory protein MRAP and StAR which account for 50% of cases. Recently nicotinamide nucleotide transhydrogenase (NNT) has been associated with a further 10% of cases. NNT generates the high concentrations of NADPH in mitochondria necessary for detoxification o...

ea0081rc2.8 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Fertility in congenital adrenal hyperplasia (CAH) patients on modified release hydrocortisone capsules (MRHC, Efmody)

Tschaidse Lea , Quinkler Marcus , Arlt Wiebke , Brac De La Perriere Aude , Linden Hirschberg Angelica , Juul Anders , Mallappa Ashwini , Merke Deborah P , Newell-Price John DC , Perry Colin Graham , Prete Alessandro , Rees Aled , Stikkelbroeck Monica , Touraine Philippe A , Coope Helen , Porter John , Ross Richard John M , Reisch Nicole

Background: Fertility in CAH women is impaired: 0.25 live births vs 1.8 in the UK population and 45% have irregular menses vs 13.6% in healthy women1. Male fertility is also impaired in CAH with oligospermia reported in 48%2. Treatment of infertility usually involves increasing the glucocorticoid dose to normalise adrenal androgens and progesterone to facilitate ovulation and implantation, respectively. Modified-release hydrocortisone (MRHC) capsules, (Ef...

ea0026p573 | Cardiovascular endocrinology and lipid metabolism | ECE2011

Low sex hormone binding globulin – strong association with metabolic syndrome in patients with acute coronary syndrome

Payer J P , Banarova A B , Koller T K , Jackuliak P J

Objective: Despite of conflicting data, reduced levels of endogenous sex hormones and especially sex hormone binding globulin (SHBG) seem to be associated with metabolic syndrome (MS). In this study we determined relationship between endogenous sex hormone levels and SHBG and components of metabolic syndrome in both sexes.Methods: In 39 men (median age 70.2) with total testosterone level in the lowest quartile of normal range (median 12.8 nmol/l) and 29 ...

ea0029oc16.3 | Female Reproduction Clinical | ICEECE2012

Anti-müllerian hormone as a predictor of ovarian response to weight loss in overweight women with polycystic ovary syndrome

Popova P. , Ivanova L. , Grineva E.

Introduction: Weight loss is a key initial treatment strategy in obese women with polycistic ovary syndrome (PCOS) and improves insulin sensitivity and metabolic risk factors. In some women with PCOS it may reduce hyperandrogenism and restore menstrual function, ovulation and fertility. The aim of this study was to reveal clinical predictors of menstrual response to weight loss in overweight women with PCOS.Design: overweight unovulatory women with PCOS ...